Core Viewpoint - Analysts project Alcon (ALC) will report quarterly earnings of $0.71 per share, a decline of 4.1% year over year, with revenues expected to reach $2.61 billion, an increase of 5.2% from the same quarter last year [1]. Earnings Projections - Revisions to earnings projections are crucial for predicting investor behavior regarding the stock, with empirical studies showing a strong correlation between earnings estimate revisions and short-term stock price performance [2]. Key Metrics Estimates - Analysts forecast 'Net Sales- Total Surgical' to reach $1.48 billion, indicating a year-over-year change of +4.3% [4]. - 'Net Sales- Total Vision Care' is expected to reach $1.13 billion, reflecting a change of +6.6% from the previous year [4]. - 'Net Sales- Total Surgical- Consumables' is projected at $786.91 million, with a year-over-year change of +6.9% [4]. - 'Net Sales- Total Surgical- Equipment/other' is estimated to be $232.70 million, showing a year-over-year change of +4.4% [5]. - 'Net Sales- Total Vision Care- Contact lenses' is expected to reach $682.51 million, indicating a change of +7.3% year over year [5]. - 'Net Sales- Total Vision Care- Ocular health' is projected at $446.40 million, reflecting a year-over-year change of +5.5% [5]. - 'Net Sales- Total Surgical- Implantables' is expected to be $464.21 million, with a minimal year-over-year change of +0.1% [6]. - 'Revenues- Other revenues' are projected to reach $17.22 million, indicating a significant year-over-year change of +23% [6]. - 'Net sales by region- United States' is estimated at $1.18 billion, reflecting a year-over-year change of +3% [6]. - 'Net sales by region- International' is expected to be $1.45 billion, indicating a year-over-year change of +7.9% [7]. Stock Performance - Alcon shares have shown a return of -0.5% over the past month, contrasting with the Zacks S&P 500 composite's +3.5% change, and the company holds a Zacks Rank 4 (Sell), suggesting it may underperform the overall market in the near future [7].

Core Insights - Alcon reported revenue of $2.45 billion for Q1 2025, a year-over-year increase of 0.3%, with EPS of $0.73 compared to $0.78 a year ago, missing the Zacks Consensus Estimate of $2.51 billion by -2.32% and EPS estimate by -3.95% [1] Financial Performance - The company's net sales by region included $1.31 billion in international sales, slightly below the $1.39 billion estimate, reflecting a year-over-year increase of 1.5% [4] - In the United States, net sales reached $1.14 billion, exceeding the $1.12 billion estimate [4] - Total Surgical net sales were $1.33 billion, below the $1.38 billion estimate, showing a year-over-year decline of 0.5% [4] - Total Vision Care net sales were $1.12 billion, slightly below the $1.14 billion estimate, with a year-over-year increase of 1.3% [4] Segment Performance - Total Surgical Consumables generated $712 million, compared to the $717.01 million estimate, marking a year-over-year increase of 3.8% [4] - Total Surgical Equipment/Other sales were $199 million, below the $223.04 million estimate, reflecting a year-over-year decline of 9.1% [4] - Total Vision Care Contact Lenses sales were $688 million, slightly below the $693.41 million estimate, with a year-over-year increase of 2.5% [4] - Total Vision Care Ocular Health sales were $432 million, below the $441.87 million estimate, showing a year-over-year decline of 0.7% [4] - Total Surgical Implantables sales were $420 million, below the $435.74 million estimate, reflecting a year-over-year decline of 3% [4] - Other revenues reached $22 million, exceeding the $17.50 million estimate, with a significant year-over-year increase of 46.7% [4] Stock Performance - Alcon's shares returned +4.7% over the past month, compared to the Zacks S&P 500 composite's +9.1% change, with a current Zacks Rank of 3 (Hold), indicating potential performance in line with the broader market [3]